Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –

– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –